You are here

Feature

Malaria and the impact of clinical research

August 22, 2017 —

The U.S. Centers for Disease Control and Prevention (CDC) estimates that in 2015, 212 million cases of malaria occurred worldwide, including the United States, and 429,000 people died from it, mostly children in Africa. There are several reasons why malaria is still so prevalent, such as the difficulty in eradicating the mosquitos that transmit the disease and the costs that many countries struggle with to build the infrastructure necessary to control the disease.

In this audio interview, FHI 360’s Ted FitzGerald, Director of Global Research Services, talks with our Director of Clinical Research in Kenya, Ghiorghis (George) Belai, about the status of malaria clinical trials. They discuss the current focus of these trials, which is developing a one-dose cure that could eventually lead to eradicating malaria. They also explain that most malaria drug development previously took place outside of Africa but is now increasingly conducted in Africa, where the drug is most needed. Our experts also explore the challenges that researchers face, as well as the contributions that FHI 360 is making to clinical trials research.

FHI 360’s Global Research Services team is working to help advance the research on treating and preventing this deadly disease. To learn more about our work, visit Global Research Services and our page on malaria.


Homepage photo credit: Michael Szpir/FHI 360